Regeneron Pharmaceuticals, Inc. (REGN)
| Market Cap | 92.65B +35.0% |
| Revenue (ttm) | 16.90B +18.6% |
| Net Income | 4.82B +5.2% |
| EPS | 45.17 +8.6% |
| Shares Out | 99.85M |
| PE Ratio | 20.54 |
| Forward PE | 13.83 |
| Dividend | $3.76 (0.41%) |
| Ex-Dividend Date | Aug 18, 2026 |
| Volume | 2,851,707 |
| Open | 869.43 |
| Previous Close | 818.77 |
| Day's Range | 839.08 - 935.35 |
| 52-Week Range | 591.52 - 935.35 |
| Beta | 0.15 |
| Analysts | Buy |
| Price Target | 869.07 (-6.34%) |
| Earnings Date | Oct 30, 2026 |
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ... [Read more]
Financial Performance
In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for REGN stock is "Buy." The 12-month stock price target is $869.07, which is a decrease of -6.34% from the latest price.
News
Regeneron price target raised to $1,000 from $865 at Piper Sandler
Piper Sandler analyst Biren Amin raised the firm’s price target on Regeneron (REGN) to $1,000 from $865 and keeps an Overweight rating on the shares.
Regeneron price target raised to $1,050 from $950 at JPMorgan
JPMorgan raised the firm’s price target on Regeneron (REGN) to $1,050 from $950 and keeps an Overweight rating on the shares after the company reported a meaningful Q3 beat, driven…
Regeneron price target raised to $1,020 from $911 at Raymond James
Raymond James raised the firm’s price target on Regeneron (REGN) to $1,020 from $911 and keeps an Outperform rating on the shares. The firm raised its price target following a…
Regeneron price target raised to $825 from $740 at Citi
Citi raised the firm’s price target on Regeneron (REGN) to $825 from $740 and keeps a Neutral rating on the shares. The firm upped Regeneron’s estimates post the better than…
Regeneron Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 revenue rose 36% and non-GAAP EPS 70%, with record sales for DUPIXENT, EYLEA HD, and LIBTAYO. Investment in a broad pipeline is set to accelerate, while 2027 R&D expense is expected to rise at a mid-teens rate.
Regeneron Pharmaceuticals Earnings release: Q3 2026
Regeneron Pharmaceuticals released its Q3 2026 earnings on October 30, 2026, summarizing the period's financial results.
Regeneron Pharmaceuticals Quarterly report: Q3 2026
Regeneron Pharmaceuticals has published its Q3 2026 quarterly earnings report on October 30, 2026.
Regeneron Pharmaceuticals Slides: Q3 2026
Regeneron Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 30, 2026.
Regeneron reports Q3 adjusted EPS $20.07, consensus $16.25
Reports Q3 revenue $5.1B, consensus $4.56B. “This was an outstanding quarter for Regeneron (REGN), with Dupixent, EYLEA HD, and Libtayo each achieving record net sales,” said Leonard S. Schleifer, M.D...
Regeneron Reports Third Quarter 2026 Financial and Operating Results
TARRYTOWN, N.Y., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the third quarter of 2026 and provided a business update.
Regeneron price target raised to $922 from $875 at Canaccord
Canaccord analyst John Newman raised the firm’s price target on Regeneron (REGN) to $922 from $875 and keeps a Buy rating on the shares. The firm updated its model ahead…
Regeneron announces longer-term data for Phase 3 C-POST trial of Libtayo
As previously reported on October 25, Regeneron (REGN) Pharmaceuticals announced longer-term data reflecting nearly four years of follow-up from the Phase 3 C-POST trial evaluating PD-1 inhibitor Libt...
Regeneron extends US agreement for additional supply of Ebola treatment
Regeneron said on Monday it extended its agreement with a US health authority to provide additional supply of its Ebola treatment, amid a growing outbreak in Africa.
Regeneron extends Inmazeb agreement with BARDA for Ebola preparedness
Regeneron (REGN) announced that it has extended its agreement with the Biomedical Advanced Research and Development Authority, or BARDA, part of the Administration for Strategic Preparedness and Respo...
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness
Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense , adding value of approximately $270 million
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
Longer-term data reflecting nearly 4 years of follow-up show a further reduction in the risk of death from 14% to 37% for those initially treated with Libtayo, despite an 88% crossover from the placeb...
Regeneron price target raised to $980 from $960 at TD Cowen
TD Cowen raised the firm’s price target on Regeneron (REGN) to $980 from $960 and keeps a Buy rating on the shares. The fim updated its model ahead of Q3…
Regeneron price target raised to $865 from $854 at Piper Sandler
Piper Sandler raised the firm’s price target on Regeneron (REGN) to $865 from $854 and keeps an Overweight rating on the shares. Ahead of Q3 2026 earnings for the group,…
Regeneron gets CHMP opinion recommending Libtayo alternative dosing schedule
Regeneron (REGN) announced that the European Medicines Agency’s, or EMA, Committee for Medicinal Products for Human Use, or CHMP, has adopted an opinion recommending the approval of an alternative dos...
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types
Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment
Regeneron assumed with Buy from Neutral at UBS
UBS upgraded Regeneron (REGN) to Buy from Neutral with a price target of $978, up from $660, after assuming coverage of the name. The shares at current levels are not…
Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension
Pasatru is the first and only FDA-approved treatment demonstrating reductions in both new HO lesions and clinician-assessed flare-ups, per results of a 56-week placebo-controlled trial in adults with ...
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins 'Closing Bell Overtime' to talk biotech innovations in China.
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo ® (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation